Collegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to Buy at StockNews.com

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) was downgraded by StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Wednesday.

A number of other research firms have also recently issued reports on COLL. Needham & Company LLC restated a "hold" rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Piper Sandler restated a "neutral" rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. HC Wainwright lifted their price target on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, September 5th. Finally, Truist Financial boosted their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $42.60.

Collegium Pharmaceutical Stock Down 0.8 %

Shares of NASDAQ:COLL traded down $0.30 on Wednesday, reaching $35.89. The company had a trading volume of 234,716 shares, compared to its average volume of 444,163. The stock has a market capitalization of $1.17 billion, a P/E ratio of 14.95 and a beta of 0.94. The stock has a 50-day moving average price of $37.69 and a 200 day moving average price of $35.39. Collegium Pharmaceutical has a twelve month low of $20.95 and a twelve month high of $42.29. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The firm had revenue of $145.28 million during the quarter, compared to analyst estimates of $143.94 million. During the same period in the previous year, the company earned $1.13 EPS. The company's revenue for the quarter was up 7.2% on a year-over-year basis. On average, equities analysts expect that Collegium Pharmaceutical will post 5.79 EPS for the current year.

Insider Buying and Selling

In other news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares of the company's stock, valued at approximately $4,602,166.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Thomas B. Smith sold 9,593 shares of the company's stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 3.98% of the stock is owned by company insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC acquired a new position in shares of Collegium Pharmaceutical in the 1st quarter worth approximately $519,000. Texas Permanent School Fund Corp increased its stake in shares of Collegium Pharmaceutical by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company's stock valued at $1,108,000 after buying an additional 369 shares in the last quarter. Gallacher Capital Management LLC acquired a new stake in shares of Collegium Pharmaceutical in the first quarter valued at $223,000. LSV Asset Management increased its stake in shares of Collegium Pharmaceutical by 188.7% in the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company's stock valued at $14,773,000 after buying an additional 248,751 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Collegium Pharmaceutical by 3.2% during the 1st quarter. Russell Investments Group Ltd. now owns 33,084 shares of the specialty pharmaceutical company's stock worth $1,284,000 after buying an additional 1,011 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.